Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 4, 2014, Pages 678-687

  Boelsterli, Urs A ^a   Lee, Kang Kwang ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antituberculosis drugs; DILI; Idiosyncratic drug induced liver injury; Mitochondria

Indexed keywords

HYDRAZINE; ISONIAZID; PHENOBARBITAL; PYRAZINAMIDE; RIFAMPICIN;

ABDOMINAL PAIN; ACUTE TOXICITY; ANTIMICROBIAL THERAPY; ARTHRALGIA; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; EOSINOPHILIA; FEVER; GENETIC SUSCEPTIBILITY; HUMAN; IC 50; IDIOSYNCRATIC LIVER INJURY; JAUNDICE; LIVER TOXICITY; META ANALYSIS (TOPIC); MITOCHONDRIAL STRESS; MITOCHONDRIAL TOXICITY; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RASH; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TOXIC HEPATITIS; VOMITING;

ANIMALS; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2E1; DRUG-INDUCED LIVER INJURY; ENERGY METABOLISM; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HOMEOSTASIS; HUMANS; HYDRAZINES; ISONIAZID; MITOCHONDRIA; OXIDATIVE STRESS; POLYMORPHISM, GENETIC;

EID: 84896364866     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12516     Document Type: Review

References (87)

1. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-490.
2. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampicin. A meta-analysis. Chest 1991; 99: 465-471.
3. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-1425.
4. Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int. J. Tuberc. Lung Dis. 2013; 17: 934-939.
5. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr. Drug Metab. 2007; 8: 839-851.
6. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J. Clin. Exp. Hepatol. 2013; 3: 37-49.
7. Verma S, Kaplowitz N. Hepatotoxicity of antitubercular drugs. In: Kaplowitz N, DeLeve L, eds. Drug-Induced Liver Disease, 3rd edn. Amsterdam: Elsevier, 2013; 483-504.
8. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am. Rev. Respir. Dis. 1972; 106: 357-365.
9. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-123.
10. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuizen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008; 23: 192-202.
11. Pessayre D, Bentata M, Degott C etal. Isoniazid-rifampicin fulminant hepatitis. A possible consequence of enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 1977; 72: 284-289.
12. Farrell GC. Drug-induced acute hepatitis. In: Farrell GC, ed. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone, 1994; 247-299.
13. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am. Rev. Respir. Dis. 1978; 117: 991-1001.
14. Kujoth GC, Hiona A, Pugh TD etal. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005; 309: 481-484.
15. Kirman CR, Sweeney LM, Meek ME, Gargas ML. Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Reg. Toxicol. Pharmacol. 2005; 38: 345-367.
16. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J. Hepatol. 2006; 45: 117-126.
17. Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem. Res. Toxicol. 2012; 25: 2567-2576.
18. Lee KK, Fujimoto K, Zhang C etal. Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes. Free Radic. Biol. Med. 2013; 65: 584-594.
19. Metushi IG, Uetrecht J. Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin. Mol. Cell. Biochem. 2014; 387: 9-17.
20. Sarich TC, Zhou T, Adams SP, Bain AI, Wall RA, Wright JM. A model of isoniazid-induced hepatotoxicity in rabbits. J. Pharmacol. Toxicol. Methods 1995; 34: 109-116.
21. Schwab CE, Tuschl H. In vitro studies on the toxicity of isoniazid in different cell lines. Hum. Exp. Toxicol. 2003; 22: 607-615.
22. Chen X, Xu J, Zhang C etal. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice. Eur. J. Pharmacol. 2011; 659: 53-60.
23. Shih TY, Young TH, Lee HS, Hsieh CB, Hu OYP. Protective effects of Kaempferol on isoniazid- and rifampicin-induced hepatotoxicity. AAPS J. 2013; 15: 753-762.
24. Shen C, Meng Q, Zhang G, Hu W. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br. J. Clin. Pharmacol. 2008; 153: 784-791.
25. Li F, Lu J, Cheng J etal. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat. Med. 2013; 19: 418-420.
26. Metushi IG, Uetrecht J. Isoniazid-induced liver injury and immune response in mice. J. Immunotoxicol. 2013. DOI: 10.3109/1547691X.2013.860644
27. Metcalfe C, Macdonald IK, Murphy EJ, Brown KA, Raven EL, Moody PCE. The tuberculosis prodrug isoniazid bound to activating peroxidases. J. Biol. Chem. 2008; 283: 6193-6200.
28. Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol. Microbiol. 2006; 62: 1220-1227.
29. Ascenzi P, Coletta A, Cao Y etal. Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N. PLoS ONE 2013; 8: e69762.
30. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 2002; 57: 799-804.
31. Kamel A, Harriman S. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discov. Today 2013; 10: e177-189.
32. Yue J, Peng RX, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol. Sin. 2004; 25: 699-704.
33. Yue J, Peng R. Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes? Br. J. Pharmacol. 2009; 157: 331-333.
34. Cheng J, Krausz KW, Li F, Ma X, Gonzalez FJ. CYP2E1-dependent elevation of serum cholesterol, trigylcerides, and hepatic bile acids by isoniazid. Toxicol. Appl. Pharmacol. 2013; 266: 245-253.
35. Liu K, Li F, Lu J, Gao Z, Klaassen CD, Ma X. Role of CYP3A in isoniazid metabolism in vivo. Drug Metab. Pharmacokinet. 2013. DOI: 10.2133/dmpk.DMPK-13-NT-089
36. Li F, Miao Y, Zhang L, Neuenswander SA, Douglas JT, Ma X. Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine. Drug Metab. Pharmacokinet. 2011; 26: 569-576.
37. Preece NE, Ghatineh S, Timbrell JA. Course of ATP depletion in hydrazine hepatotoxicity. Arch. Toxicol. 1990; 64: 49-53.
38. Waterfield CJ, Delaney J, Kerai MDJ, Timbrell JA. Correlations between in vivo and in vitro effects of toxic compounds: studies with hydrazine. Toxicol. in Vitro. 1997; 11: 217-227.
39. Wakabayashi T, Teranishi MA, Karbowski M etal. Functional aspects of megamitochondria isolated from hydrazine- and ethanol-treated rat livers. Pathol. Int. 2000; 50: 20-33.
40. Hussain SM, Frazier JM. Cellular toxicity of hydrazine in primary rat hepatocytes. Toxicol. Sci. 2002; 69: 424-432.
41. Ghatineh S, Morgan W, Preece NE, Timbrell JA. A biochemical and NMR spectroscopic study of hydrazine in the isolated rat hepatocyte. Arch. Toxicol. 1992; 66: 660-668.
42. Sanins SM, Timbrell JA, Elcombe C, Nicholson JK. Proton NMR spectroscopic studies on the metabolism and biochemical effects of hydrazine in vivo. Arch. Toxicol. 1992; 66: 489-495.
43. Nicholls AW, Holmes E, Lindon JC etal. Metabonomic investigations into hydrazine toxicity in the rat. Chem. Res. Toxicol. 2001; 14: 975-987.
44. Bollard ME, Keun HC, Beckonert O etal. Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol. Appl. Pharmacol. 2005; 204: 135-151.
45. Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J. Pharmacol. Exp. Ther. 1999; 289: 695-702.
46. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht J. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther. 2011; 89: 911-914.
47. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976; 193: 901-903.
48. Metushi IG, Sanders C, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-CYP antibodies in patients with isoniazid-induced liver failure. Hepatology 2013. DOI: 10.1002/hep.26564
49. + adduct. Antimicrob. Agents Chemother. 2012; 56: 28-35.
50. Bekierkunst A. Effect of isoniazid on preservation of nicotinamide dinucleotide in animal cells. Arch. Biochem. Biophys. 1967; 118: 549-555.
51. Waner T, Nyska A. The toxicological signficance of decreased activities of blood alanine and aspartate aminotransferase. Vet. Res. Commun. 1991; 15: 73-78.
52. O'Brien PJ, Slaughter MR, Polley SR, Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab. Anim. 2002; 36: 313-321.
53. Ng W, Lobach ARM, Zhu X etal. Animal models of idiosyncratic drug reactions. Adv. Pharmacol. 2012; 63: 81-135.
54. Pastorino JG, Simbula G, Gilfor E, Hoek JB, Farber JL. Protoporphyrin IX, an endogenous ligand of the peripheral benzodiazepine receptor, potentiates induction of the mitochondrial permeability transition and the killing of cultured hepatocytes by rotenone. J. Biol. Chem. 1994; 269: 31041-31046.
55. Timperio AM, Rinalducci S, Zolla L. Hydrazide derivatives produce active oxygen species as hydrazine. Bioorg. Chem. 2005; 33: 459-469.
56. Tafazoli S, Mashregi M, O'Brien PJ. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol. Appl. Pharmacol. 2008; 229: 94-101.
57. Sun Q, Harper TW, Dierks EA etal. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug Metab. Dispos. 2011; 39: 1674-1679.
58. Enriquez-Cortina C, Almonte-Becerril M, Clavijo-Cornejo D etal. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage. Toxicol. Sci. 2013; 135: 26-36.
59. Lian Y, Zhao J, Xu P etal. Protective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice. PLoS ONE 2013; 8: e72058.
60. Chen Y, Xue P, Hou Y etal. Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol. Appl. Pharmacol. 2013; 273: 435-441.
61. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fund. Clin. Pharmacol. 2008; 22: 335-353.
62. Lemasters JJ. Hepatotoxicity due to mitochondrial injury. In: Kaplowitz N, DeLeve L, eds. Drug-Induced Liver Disease, 3rd edn. Amsterdam: Elsevier, 2013; 85-100.
63. Karbowski M, Kurono C, Wozniak M etal. Free radical-induced megamitochondria formation and apoptosis. Free Radic. Biol. Med. 1999; 26: 396-409.
64. Jones M, Nunez M. Liver toxicity of antiretroviral drugs. Semin. Liver Dis. 2012; 32: 167-176.
65. Blas-Garcia A, Apostolova N, Ballesteros D etal. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010; 52: 115-125.
66. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 2011; 54: 1009-1019.
67. Bumpus NN. Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. Toxicol. Appl. Pharmacol. 2011; 257: 227-234.
68. Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M, Esplugues JV, Apostolova N. Profile of stress and toxicity gene expression in human hepatic cells treated with efavirenz. Antiviral Res. 2012; 94: 232-241.
69. Apostolova N, Gomez-Sucerquia LJ, Alegre F etal. ER stress in human hepatic cells treated with efavirenz: mitochondria again. J. Hepatol. 2013; 59: 780-789.
70. Mitchell JR, Thorgeirsson UP, Black M etal. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin. Pharmacol. Ther. 1975; 18: 70-79.
71. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6: 295-298.
72. Gupta VH, Amarapurkar DN, Singh M etal. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J. Gastroenterol. Hepatol. 2013; 28: 1368-1374.
73. Huang YS, Chern HD, Su WJ etal. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
74. Knockaert L, Fromenty B, Robin MA. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiological role in liver injury and obesity. FEBS J. 2011; 278: 4252-4260.
75. Lieber CS. Cytochrome P450 2E1: its physiological and pathological role. Physiol. Rev. 1997; 77: 517-544.
76. Li C, Long J, Hu X, Zhou Y. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32: 859-868.
77. Nanashima K, Mawatari T, Tahara N etal. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberulosis patients. Tuberculosis 2012; 92: 253-259.
78. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 2002; 166: 916-919.
79. James L, Roberts D. Isoniazid hepatotoxicity: progress in understanding the immunologic component. Hepatology 2013. DOI: 10.1002/hep.26707
80. Nicholson JK, Holmes E, Kinross J etal. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.
81. Haiser HJ, Turnbaugh PJ. Is it time for a metagenomic basis of therapeutics? Science 2012; 336: 1253-1255.
82. Swann J, Wang Y, Abecia L etal. Gut microbiome modulates the toxicity of hydrazine: a metabonomic study. Mol. Biosyst. 2009; 5: 351-355.
83. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-1537.
84. WHO. Treatment of Tuberculosis: Guidelines, 4th edn. WHO/HTM/TB/2009.420. WHO Press, Geneva, Switzerland, 2010. Available from URL: error type=herf without www.who.int/publications/2010/9789241547833/en/
85. Hoffmann CJ, Charalambous S, Thio CL etal. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2013; 21: 1301-1308.
86. Kappelhoff BS, van Leth F, Robinson PA etal. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther. 2005; 10: 489-498.
87. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br. J. Pharmacol. 2010; 160: 2069-2084.